Psoriatic arthritis
Conference Coverage
Brodalumab raced past ustekinumab to PASI 100
PARIS – Pooled analysis of phase 3 trials spotlights one clinical setting where brodalumab is particularly advantageous.
Conference Coverage
Longterm maintenance of PASI 75 responses observed with tildrakizumab
PARIS – More than 90% of PASI 75 responders to tildrakizumab at 6 months maintained at least a PASI 75 response at 148 weeks.
Conference Coverage
CONDOR trial: Most psoriasis patients can be downshifted to reduced-dose biologics
PARIS – Results of the first-ever randomized trial of biologic dose reduction in well-controlled psoriasis patients are reported.
From the Journals
Back pain criteria perform well in patients with active axial psoriatic arthritis
The tool performed suboptimally overall, but had good sensitivity and specificity in patients with active symptoms.
Latest News
Positive results reported for ixekizumab versus adalimumab in PsA
Lilly described top-line results for the SPIRIT-H2H trial.
Conference Coverage
Natural killer cells implicated in psoriatic arthritis
CHICAGO – Translational study brings a genetic test for psoriatic arthritis one step closer.
From the Journals
Algorithm proposes approach for managing TNF inhibitor–induced psoriasis
Guidelines
ACR, NPF unveil new psoriatic arthritis treatment guideline
This marks the first such recommendations to be assembled using Grading of Recommendations Assessment, Development and Evaluation (GRADE)...
Conference Coverage
Filgotinib shows efficacy, safety in RA phase 3 and PsA phase 2 trials
CHICAGO –
Conference Coverage
Weight loss cuts risk of psoriatic arthritis
CHICAGO – An empowering new message for psoriasis patients.
Conference Coverage
Topical treatments remain a good option for psoriasis
LAS VEGAS – Creams and ointments still have a role, even in the age of biologics.